123696澳门论坛

Shanghai, China, August 31, 2023 – Genor Biopharma (Stock code: 6998.HK) today announced its interim results for 2023, sharing the company's business progress, financial data, highlights during the period, and future development prospects.

For the third consecutive year, Genor Biopharma won the title of "Chinese Antibody Drug Companies Innovation TOP 30". Focus on the potential global FIC/BIC innovation pipeline, and is actively exploring cooperation projects between its platform for early discovery of highly differential T-cell Engager / bi-specific/multi-specific antibodies in immune-oncology / BsADC and different innovative technology platforms to further promote global innovation through cooperation.

Based on the efficacy and safety data presented in the LEONARDA-1, Lerociclib (GB491) is expected to be a more reliable clinical option for patients with HR+/HER2- advanced breast cancer. Lerociclib (GB491) could become a preferred option among CDK4/6 inhibitors for patients with suboptimal recovery of myelosuppression after chemotherapy and suboptimal gastrointestinal / hepatic function or patients with poor tolerability.

Genor Biopharma (Stock code: 6998.HK) announced that the latest research data of LEONARDA-1 were selected by 2023 ASCO for the ASCO Daily Release, which was published in the ASCO Daily News Column on its website on May 25 (EST). Entitled "Lerociclib/Fulvestrant May Reduce Risk of Disease Progression in Advanced HR-Positive/HER2-Negative Breast Cancer", the article presents data from the Phase III clinical study of LEONARDA-1, citing the views of the lead author Prof. Binghe Xu, MD, PhD, the academician of the Chinese Academy of Engineering, the Head of Medical Oncology at Cancer Hospital affiliated with Chinese Academy of Medical Sciences.

Genor Biopharma (Stock code: 6998.HK) announced today that the results of the LEONARDA-1 phase III clinical trial in advanced HR+/HER2- breast cancer will be posted for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6.